by a Ca 2+ uniporter and the driving force for its action is the mitochondrial membrane potential (9) . A rapid access mode (RAM) of Ca 2+ uptake into mitochondria has also been described (10) . The precise role that each of these pathways play in buffering cytoplasmic Ca 2+ following plasma membrane NMDA receptor stimulation is not well understood.
Interestingly, this pool of Ca 2+ appears to have privileged access to mitochondria (11) , although how this occurs is not known. Considerable evidence has amassed that glutamate, in addition to its role as a nervous system neurotransmitter, may also activate receptors on a variety of non-neuronal cells including osteoclasts (12) , platelets (13) , keratinocytes (14, 15) as well as several carcinomas (16, 17) . In several of these cell types, the expression of NMDA receptors has been reported (18) (19) (20) (21) .
In pancreatic islet cells, intracellular glutamate may be coupled to insulin secretion (22) . Although these later findings have been debated (23) , they raise the intriguing possibility that glutamate could serve as an important intracellular signaling factor. Based on these observations and the link between NMDAstimulated mitochondrial uptake of Ca 2+ , we sought to determine whether purified mitochondria were sensitive to the direct actions of NMDA receptor agonists.
EXPERIMENTAL PROCEDURES
Animals-Male Sprague-Dawley rats 12-16 weeks of age were used for these studies. All animal use procedures were in accordance with the NIH Guide for the Care and Use of Laboratory Animals and were approved by the University of Kentucky and Hunter Holmes McGuire Veterans Administration Institutional Animal Care and Use Committees. Mitochondrial preparation -A recently described method (24) was used with the modification that samples of cerebral cortex were placed into a large manual glass homogenizer containing 5 ml of icecold isolation buffer (20 mM HEPES, 215 mM mannitol, 75 mM sucrose, 0.1% BSA, 1 mM EGTA, pH 7.2) which contained several blockers to prevent the influx and efflux of Ca 2+ during the preparation of mitochondria (25, 26) . This "locking buffer" contained 16 µM ruthenium red to block the mitochondrial inward transport of Ca 2+ via the uniporter and RAM and extrusion via the sodium-independent antiporter, 15 µM cyclosporin A to prevent movement of Ca 2+ via the permeability transition and 10 µM CGP-37157 to inhibit outward flux of Ca 2+ via the sodiumdependent antiporter. Neither Na + , which is required for activation of the sodium-independent antiporter nor EGTA/EDTA was included in this buffer. Mitochondrial Calcium Assays -For single timepoint mitochondrial calcium concentrations ([Ca 2+ ] m ) determination, 50 µg of mitochondria were incubated in the assay buffer (20 mM HEPES, 215 mM mannitol, 75 mM sucrose, 2.5 mM KH 2 PO 4 and 0.1% fatty acid-free BSA, pH 7.2) containing 5 µM CaCl 2 and various combinations of NMDA receptor agonists and antagonists in a final volume of 100 µl. Following a 30 min incubation period at room temperature, the samples were centrifuged at 10,000 xg for 10 min at room temperature. The mitochondrial pellet was taken up in 100 µl assay buffer and added to a 96 well culture dish to which 5µM Calcium Green 5-N (Life Technologies, Carlsbad, CA) was added.
Fluorescence (baseline) measurements were made in the intact mitochondria and then repeated 15 min following the addition of 1% Triton X-100 to lyse mitochondria and liberate matrix Ca 2+ . Fluorescence was measured using an excitation wavelength of 485 nm and emission wavelength of 532 nm. In a single experiment, [Ca 2+ ] m was measured directly using the fluorescent probe Rhod-2 (Life Technologies, Carlsbad, CA). All steps performed were identical to those describe above with the exceptions that mitochondria were pre-loaded with 10µM Rhod-2 prior to a 30 min incubation with NMDA and/or calcium and the mitochondria then washed 3 times. Fluorescence was measured using an excitation wavelength of 552 nm and emission wavelength of 581 nm. Protein concentrations were determined using the Bradford protein assay (Pearce, Rockford, IL). All experiments were replicated three to six times.
The effect of NMDA on [Ca 2+ ] m was also measured in real-time.
Mitochondria were prepared as described above with the exception that no calcium transporter blocking agents were included in either the isolation or assay buffers. A 250 μg sample of mitochondrial protein was added to a cuvette which contained 2 ml assay buffer (20 mM Tris HCl, 150 mM sucrose, 50mM KCL, 2mM KH 2 PO 4 and 5 mM succinate, pH 7.2) and 0.5μM Calcium Green 5-N. Bolus additions of calcium (5 M) were injected at regular intervals in the absence or presence of 10 M NMDA. Fluorescence was measured in a Perkin Elmer LS 55 spectrofluormeter with excitation and emission wavelengths of 500 and 535 nm, respectively. Samples were continuously stirred and maintained at 37° C during the recordings. Western Blot Analysis -Samples of either cytosol, synaptic membrane fragments or mitochondria were probed with antibodies using standard methodology. The following primary antibodies were used at a dilution of 1:2000: -actin (SigmaAldrich, St. Louis, MO), cytochrome oxidase subunit IV (COX IV; Molecular Probes, Eugene, OR), Lamp -1, calnexin (Sigma, St. Louis, MO), NR2a and NR1 (Molecular Probes, Eugene, OR). Antibodies against synaptophysin (Abcam, Cambridge, MA) and -subunit Na + ,K + -ATPase (BD Transduction Laboratories, Franklin Lakes, NJ) were used at a dilution of 1:20,000. ECL detection reagent was used to develop gels which were imaged either directly on film or using a Fuji LS4000 image analyzer. In some instances, films were scanned and the optical densities measured. Electron Microscopy -Immunogold labeling was performed on rat brain tissue (hippocampal CA1 subregion) and mitochondrial pellets that were fixed with 4% paraformaldehyde + 0.25% glutaraldehyde in Sorenson's buffer and infiltrated with LR-White resin using standard procedures. For routine electron microscopy, mitochondrial pellets were simply fixed and infiltrated. Sections were cut on a Leitz ultramicrotome and collected on nickel grids. Immunolabeling was performed using 1:50 -1:25 dilution of a monoclonal antibody against rat NR2a (Invitrogen, Carlsbad, CA) and 12 -15 nm colloidal gold conjugated to a goat anti-rabbit secondary antibody (1:25; Jackson ImmunoResearch Laboratories, Inc., West Grove, PA). Sections were counterstained with uranyl acetate and lead citrate. The grids were examined and photographed on a Hitachi H7100 transmission electron microscope. Mitochondrial membrane solubilization -Inner and outer mitochondrial membranes were separated using digitonin fractionation. Briefly, 1mg of purified mitochondria was added to 1% digitonin on ice for 10 minutes after which the sample was diluted with an equal volume of isolation buffer followed by centrifugation at 12,000 xg for 10 minutes at 4 0 C. The resultant supernatant contained the outer mitochondrial membrane (OMM) and the pellet contained inner membrane-containing mitoplasts (IMM). The supernatant was centrifuged at 145,000 xg for 1 hour at 4 0 C and the resultant pellet resuspended in 1 ml of 100 mM sodium carbonate (Na 2 CO 3 ) for 5 minutes on ice and then centrifuged at 145,000 xg at 4 0 C to obtain highly purified OMM. The mitoplast fraction was resuspended in isolation buffer on ice, sonicated for 1 minute, and centrifuged for 12,000 xg at 4 0 C for 10 minutes. The resulting supernatant was centrifuged at 145,000 x g at 4 0 C for 1 hour. The pellet containing the IMM was resuspended in 1 ml of 100 mM sodium carbonate (Na 2 CO 3 ) for 5 minutes on ice and centrifuged at 145,000 xg at 4 0 C to obtain pure IMM. For Western blotting, the OMM and IMM were probed with antibodies against the voltage-dependent anion channel (VDAC) and adenine nucleotide translocator (ANT), respectively (Abcam, Cambridge, MA). Bcl-2-NR1-NR2a Fusion Protein Construct -GRINA and GRIN2A genes were sub-cloned into a single bi-cistronic vector pCMV-BICEP™-4 (Sigma, St. Louis, MO) in tandem to create fusion protein of NR1-NR2A. The vector consists of multiple cloning sites: for GRINA the site was EcoRI/XbaI and for GRIN2A the site was Hind III/EcoRI. To target the mitochondria, the Bcl-2 mitochondrial leader sequence was added. The leader amino acid sequence was MLSLRQSIRFFKPATRTL. The N terminus of the sequence was modified by adding the unique restriction site MseI and the C terminus was modified by adding the BamHI, which allowed insertion of the leader sequence immediately downstream of the promoter and upstream of the NR1-NR2a sequence. Also, the reading frames of the leader and both the genes (GRINA-GRIN2A) were continuous. The construct was amplified using the following primers: forward 5'-CGGGAGAATGTCTGGACCTA-3' and reverse 5'-TTCTGTGACCAGTCCTGCTG-3'. A mutant construct was created by introducing a single point mutation (T648A) in the glutamate binding region of GRINA using site directed mutagenesis. (Agilent Technologies, Santa Clara, CA).
Cell Culture and NMDA Receptor Overexpression -GT1-7 cells, which are immortalized hypothalamic neurons, were cultured in modified Dulbecco's Minimal Essential Medium (DMEM) containing 4500 mg/L glucose, 110 mg/L pyruvate and 548 mg/L L-glutamine (Mediatech, Herndon VA), 10% fetal calf serum (Invitrogen, Carlsbad, CA) and 1% penicillin/streptomycin (Gibco, Grand Island NY). Cultures were maintained at 37°C in an incubator kept at 5% CO 2 . Cultures were passed, by treating with 1x trypsin (Sigma, St Louis, MO) diluted in 1x phosphate buffered saline for 1-2 minutes at room temperature. Culture flasks were passed every week and for all studies, cells were used between passages 5 and 10.
Using six well plates that were seeded at a density of 100,000 cells/well, transient transfection was performed using the commercially available transfecting agent Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Briefly, transfections were carried out in wells containing 2 ml of medium and the cells ~80% confluent. One µg of DNA and 7 µl of Lipofectamine 2000 in 3 ml of Opti-MEM (Invitrogen, Carlsbad, CA) were added to each well. After a 6 hr incubation, the transfection mixture was replaced with culture medium. In initial experiments using a GFP-tagged construct, expression efficiency was calculated to be ~85%. In these experiments, expression was confirmed at 48-72 hours by obtaining preparing mitochondria form the cells and performing Western blot analysis for NR1 and NR2a. Toxicity Assays -The effects of glutamate agonists were examined at 48-72 hrs following transfection. Cells were exposed to 25 µM Lglutamate for 15 minutes after which time the medium was replaced with fresh medium. Twentyfour hours later, live and dead cells were quantified using LIVE/DEAD Viability/Cytotoxicity Kit, (Invitrogen, Carlsbad, CA) using the protocol provided by company. Live and dead cells were visualized with a Zeiss Axiovert fluorescent microscope.
A manual counter was used to record the number of live and dead cells. At least 150-200 cells per well were counted (at 12, 3, 6 and 9 o'clock and the center of each well) and each sample was run in triplicate. For calcium assays, cells were exposed to 25 µM L-glutamate for 15 minutes after which mitochondria were prepared from 10 6 cells in locking buffer and calcium quantified as previously described. Experiments were repeated three times. ATP Assay -Non-transfected, transfected and mutant transfected GT1-7 cells were exposed to 25 µM L-glutamate for 30 minutes after which time reaction buffer was added to the wells and ATP concentrations were measured using a commercially available ATP kit (Molecular Probes, Eugene OR). A standard curve was generated using standards provided by the company. Samples were measured in a Molecular Device Spectra Max Plus luminometer at 560 nm and ATP levels extrapolated from the standard curve. Each experiment was repeated three times. Gene Silencing -Human NMDA NR1 (transcript variant 2) siRNA with the sequence 5'-ACA ATG AGC GTG CGC AGT A-3' was obtained commercially (Integrated DNA Technologies, Coralville, IA). One μg of siRNA and 6 μl of Lipofectamine 2000 were mixed in 2 ml Opti-MEM medium (Invitrogen, Carlsbad, CA) for 15 minutes at room temperature and then applied to 90% confluent GT1-7 cells. Cells were cultured in a 5% CO 2 incubator at 37°C for 72 hours. Cells in the control groups were either non-transfected or transfected with the scrambled siRNA (5'-GCUUACUGCGUAUAGGUCACA-3').
The efficiency of NMDA NR1 gene silencing was determined using Western blot analysis. Cell lysates (10 μg protein) were loaded onto a 4 -12% SDS resolving gel and then transferred to a nitrocellulose membrane. The membrane was incubated with monoclonal anti-human NR1 antibody as primary antibodies (Invitrogen, Carlsbad, CA) at a 1:2000 dilution followed by a goat anti-mouse secondary antibody at a dilution of 1:5000. NMDA NR1 was detected using an enhanced chemiluminescence detection kit (Pierce, Rockford, IL) and quantified using Multi Gauge software (Fujifilm, Valhalla, NY). For calcium uptake studies, mitochondria were prepared from 10 6 cells in "locking buffer" and incubated for 30 min with calcium in the absence or presence of NMDA as described above. Statistical Analysis -Due to the lack of variation within replicates, experiments were typically carried out three times except where noted. The comparison of multiple treatment groups to controls was conducted using a one-way ANOVA with Fisher's PLSD post-hoc testing when required.
F-distribution calculations were performed and confirmed that, even with the small sample sizes, there was homogeneity of variance between groups. All data and error bars are presented +/-S.E.M.
RESULTS
Assessment of mitochondrial preparation purity -We performed electron microscopy on thin sections prepared from a final mitochondrial pellet and observed an abundance of intact mitochondria and some membrane fragments but absence of synaptosomes and other identifiable intracellular organelles (Fig. 1a) .
Western blot analysis confirmed the absence of cytoplasmic ( -actin), endosomal (Lamp-1), endoplasmic reticulum (calnexin) and plasma (ATPase) and synaptosomal (synaptophysin) membrane contaminants (Fig. 1b  and c ) in the mitochondrial (COX-IV) fraction. To quantify the purity of our preparation, we generated a low power electron microscopicphotomontage and counted a total 1,606 mitochondria yet only 51 non-mitochondrial elements. This technique therefore indicates our preparation consists of ~97% mitochondria.
Calcium uptake assays -In our initial studies, mitochondria were exposed to Ca 2+ in the presence of various compounds and [Ca 2+ ] m was quantified in "locking buffer" (Fig. 2) . Following exposure to the biologically active L-glutamate isoform there was an almost two-fold increase in [Ca 2+ ] m compared to untreated mitochondria (54.1 + 2. ] m induced by each of the NMDA receptor agonists (Fig. 2b) . Although glycine (Fig. 2c) , which is a requisite coactivator of plasma membrane NMDA receptors In cells, glutamate, is transported into mitochondria by carrier proteins with either the coincidental co-transport of protons into the mitochondrial matrix or in exchange for hydroxyl radicals (28) . Recently, two distinct human isoforms of the transporter have been expressed in E. coli (29) . Although mitochondrial calcium uptake has not been linked to the transport of glutamate, we sought to exclude this process as a potential route of Ca 2+ uptake. Exposure of rat brain mitochondria to L-glutamate, NMDA or QA in the presence of each of several glutamate transporter inhibitors failed to attenuate the glutamate-stimulated increase in [Ca 2+ ] m (Fig 2d) . Although the use of blocking agents allowed us to uncover an NMDA-sensitive site, we wanted to determine whether NMDA could enhance mitochondrial Ca 2+ uptake in real-time in the absence of such agents.
As shown in the representative tracing (Fig. 3a) , exposure of mitochondria to 5 M Ca 2+ results in a transient deflection of the fluorescent signal upward, indicating an increase in extramitochondrial Ca 2+ , followed by a partial return to baseline, resulting from sequestration of Ca 2+ by mitochondria. This pattern recurred three more times after which the buffering of Ca 2+ reached a plateau. In contrast, when mitochondria were exposed to Ca 2+ in the M NMDA, they were able to take up calcium for a total of twelve bolus additions before reaching their maximum buffering capacity (Fig. 3b) . Moreover, samples co-incubated with calcium and NMDA sequestered nearly all the calcium added to the sample. Consistent with our findings using Calcium Green 5-N, there was an ~33% increase in [Ca 2+ ] m using Rhod-2 following exposure to calcium and NMDA compared to untreated, control mitochondria (35.78+1.2 FU vs. 26.9+0.9 FU; p<0.001). As predicted, D-glu had no effect on [Ca 2+ ] m compared to control (27.9+0.3 FU vs. 26.9+0.9 FU). Although the magnitude of change with Rhod-2 was less than that seen with Calcium Green 5-N, this is likely due to the fact that Rhod-2 measures free matrix calcium and our method using Calcium Green 5-N reflects total matrix calcium. The findings obtained with Rhod-2, therefore, support the validity of our data using Calcium Green 5-N.
Electron microscopic examination of NMDA receptor subunit NR2a -When thin sections prepared from a fixed, synaptosome-derived mitochondrial pellet were labeled with an antibody against the C-terminal region of the NR2a subunit, gold particles were detected on the surface of mitochondria (Fig 4a) . Using tissue sections prepared from CA1 of the rat hippocampal formation, a region rich in plasma membrane NMDA receptors (30, 31) , labeling of mitochondria was observed that was clearly above background ( Fig. 4b) and considerably more extensive than described in two previous electromicrographic studies in which only sporadic labeling of mitochondria was noted (32, 33) . Of significance, gold particles tended to occur in clusters, which are taken as an index of specific epitope recognition. No gold particles were associated with mitochondria when the primary antibody was omitted in either preparation.
Submitochondrial localization of NR1 and NR2a-To elucidate which mitochondrial membrane(s) NMDA receptor units were located, the outer mitochondrial membrane was solubilized and stripped from the inner membrane and both fractions probed with antibodies against NR1 and NR2a. As noted in Fig. 4c , both NR1 and NR2a immunoreactivity were noted only in the inner membrane fraction.
Effect of NMDA receptor overexpression in mitochondria -In light of the previous findings, we selectively overexpressed NMDA receptors on mitochondria and examined the effects in an in vitro model of excitotoxicity. To accomplish this, we targeted NR1 and NR2a subunits, coexpression of which results in a functional receptor with pharmacological characteristics nearly indistinguishable from native NMDA receptors (34) , into mitochondrial membranes of GT1-7 cells using a Bcl2 leader sequence. This leader sequence has been shown to insert Bcl2 into both the outer (35) and inner (36) mitochondrial membranes. GT1-7 is an immortalized GnRH neuronal cell line (37) , with well-characterized plasma membrane NMDA receptors (38) . In nontransfected cells, both NR2a and NR1 protein respectively, were found in the mitochondrial and plasma membrane fractions (Fig. 5a ). In cells transfected with NR1-NR2a, there is an approximately 5-fold increase in mitochondrial both subunits (Fig. 5a ) with no discernible change in plasma membrane levels. Twenty-four hours following a brief exposure of non-transfected cells to 25 µM L-glutamate, there was ~35% cell death (Fig. 5b) . In cells transfected with the NR1-NR2a cassette 48 hrs prior to glutamate treatment, cell death was reduced to ~10%. Transfection of GT1-7 cells with mutant NR1-NR2a conferred no neuroprotection.
In a parallel experiment, GT1-7 cells were incubated with L-glutamate after which the mitochondria were isolated and [Ca 2+ ] m quantified (Fig. 5c ). Transfected cells that were not exposed to glutamate revealed nearly identical levels of We next examined the effect of transfection with a Bcl-2-NR1-NR2a fusion protein on ATP production following an excitotoxic insult (Fig.  5d) . Compared to ATP levels in untreated, nontransfected cells (1.9 + 0.03 pmol), cellular ATP levels in cells transfected with either NR1-NR2a or mutant NR1-NR2a were unchanged (1.9 + 0.02 pmol and 1.9 + 0.03 pmol, respectively) indicating that transfection itself has no effect on basal cellular ATP levels. In non-transfected cells briefly exposed to 25µM L-glutamate, there was also no increase in cellular ATP levels (2.1 + 0.02 pmol). In contrast, when cells transfected with NR1-NR2a subunits were treated with glutamate, there was a two-fold increase in ATP levels (4.1 + 0.22 pmol) while mutant NR1-NR2a transfected cells treated with glutamate resulted in basal levels of ATP (2.0 + 0.02 pmol).
Effect of silencing NMDA receptor subunit NR1 on mitochondrial calcium uptake -The ability of mitochondria to sequester Ca 2+ was examined in GT1-7 cells treated with siRNA against the NR1 subunit, the presence of which is needed for successful targeting of NR2a into the plasma membrane (39) . In mitochondria isolated from cells transfected with siRNA against NR1, there was an approximate 65% reduction in mitochondrial NR1 protein expression (Fig. 6a and  b) . Preparations of mitochondria from nontransfected (control) cells, siRNA-and scramble-RNA-transfected cells all demonstrated similar levels of [Ca 2+ ] m following a 30 minute incubation in the presence of calcium (Fig. 6c) . Consistent with our initial findings (Fig. 2a) , when mitochondria isolated from non-transfected, GT1-7 cells were exposed to both NMDA and calcium, there was an approximate two-fold increase in compared to mitochondria exposed to calcium alone.
When NR1 was silenced, however, exposure to calcium and NMDA did not increase [Ca 2+ ] m . In contrast, when mitochondria were prepared from cells transfected with a scrambled siRNA, the ability to sequester calcium returned to control levels, as revealed by a two-fold increase in [Ca 2+ ] m following exposure to both calcium and NMDA compared to mitochondria in which there was no change in NR1 protein expression.
DISCUSSION
Currently, two principal routes have been described by which calcium can enter nervous system mitochondria: the high capacity mitochondrial uniporter (9) and low capacity rapid access mode (RAM) (10) . The uptake of calcium via the uniporter, the structure of which has recently been described (40) , is driven by the mitochondrial membrane potential and has been linked to both energy production (41, 42) as well as cell death pathways via induction of the mitochondrial permeability transition (43) . The role of RAM is less clear. The results of the present study indicate that there may yet be another conduit for calcium entry that is activated by traditional NMDA receptor agonists. To unmask this effect, both the calcium uniporter and RAM as well as efflux pathways were blocked during our initial studies to prevent movement of calcium via these pathways. The lack of increase in [Ca 2+ ] m in "locked" mitochondria exposed to calcium compared to control mitochondria (Fig.  1a) strongly suggests that the accumulation of calcium following treatment with NMDA agonists cannot be ascribed to the uptake of calcium through these known channels. Moreover, our findings indicate that glutamate transporters were not responsible for the entrance of calcium into mitochondria. Real-time calcium measurements in "unlocked" mitochondria confirm these observations and further suggest that glutamatelike compounds enhance mitochondrial calcium retention capacity.
Several steps were taken to ensure the purity of the mitochondrial preparations. First, samples were subjected to rapid decompression in a nitrogen cell bomb, which ruptures synaptosomes, thereby eliminating them from the preparation (24) . The resultant samples, which were then centrifuged through a Percoll gradient and washed several times to remove other contaminants, were shown to free of synaptosomes and other potential membrane compartments based on electron microscopic and western blot analyses. In light of the high degree of purity (~97%) of the preparations, we conclude that the elevation in [Ca 2+ ] m following exposure to NMDA agonists is the result of accumulation of this ion in mitochondria and not other compartments.
In the present study, uptake of Ca 2+ by nontransfected and mutant NR1-NR2a-transfected cells following treatment with glutamate showed an ~25% increase in [Ca 2+ ] m , which was associated with approximately 35% cell death. In contrast, in cells overexpressing NR1-NR2a, treatment with glutamate caused a two-fold increase in [Ca 2+ ] m , yet cell death was significantly depressed. The present findings suggest that uptake of Ca 2+ via mitochondrial-targeted NMDA receptors may serve a very different role. Since increases in [Ca 2+ ] m can activate several enzymes of the TCA cycle with the subsequent production of NADH (44, 45) , we speculate that activation of mitochondrial, NMDA-sensitive sites provides an early signal to stimulate oxidative phosphorylation in an attempt to enhance energy supplies and mitigate damage that might otherwise proceed unchecked in an excitotoxic environment. The coincidental increase of ATP production in NR1-NR2a-transfected cells following exposure of cells to glutamate supports this notion.
One issue that was not addressed in this study is the mechanism whereby the mitochondrial NMDA-sensitive site can initiate a specific response in the presence of millimolar levels of cytoplasmic glutamate. Two possible explanations can be offered. First, it has been demonstrated that, following the stimulation of plasma membrane NMDA receptors, there is an increase in cytosolic calcium and that this pool of calcium has privileged access to mitochondria (11) . Based on our findings, we would posit that due to the high levels of glutamate, this site is constitutively active but only following an increase in cytosolic calcium "microdomains" resulting from plasma membrane NMDA receptor activation, can calcium specifically enter the mitochondria. Indeed, calcium microdomains have been shown to regulate a number of cellular processes in distinct regions of the cell (46) . Alternatively, it is conceivable that there is another messenger, which in the presence of elevated calcium, activates the mitochondrial NMDA-sensitive site. The location of both NR1 and NR2a subunits in the inner mitochondrial membrane is consistent with the role of this site as a point of calcium entry into the matrix, yet how they target this structure requires investigation.
The elevation in [Ca 2+ ] m following treatment with known receptor agonists and antagonists, suggest that there exists a site with characteristics similar to plasma membrane NMDA receptors. The observed immunoreactivity against NR2a and prevention of calcium uptake in mitochondria in which NR1 was silenced, further suggest that this site shares sequence homology to plasma membrane NMDA receptors. It is not clear, however, whether this site is distinct or part of a larger molecular entity.
The ability of mitochondria to sequester calcium in the presence of inhibitors of both the calcium uniporter and permeability transition argues against an association with either of these structures. Studies are currently underway to identify and further characterize the nature of this putative receptor.
FIGURE LEGENDS
FIGURE 1. Assessment of mitochondrial purity. A. Electron photomicrograph of a mitochondrial pellet reveals a sample rich in mitochondria and lacking other recognizable intracellular organelles. Bar = 500 nm. B. Western blot reveals both NR1 and NR2a labeling in cytosolic (C) and mitochondrial (M) samples. There is no labeling of the cytoplasmic marker -actin, endosomal marker LAMP-1 or endoplasmic reticulum marker calnexin (Cal) in the COX-IV-labeled mitochondrial fraction. C. There is considerably more NR2a labeling in the synaptic membrane fraction (S) compared to mitochondrial fraction. The marker for plasma membrane (ATPase) is virtually absent in the mitochondrial fraction and marker for synaptic vesicles (Syn) only minimally present. . Mitochondria (250 µg) were exposed to 5 µM bolus additions of Ca 2+ in the absence (A) or presence (B) of 10 µM NMDA. In the absence of NMDA, mitochondria partially buffer 4 bolus additions of Ca 2+ before uptake reaches a plateau. When NMDA is included, mitochondria sequester a total of 13 bolus additions before reaching maximum buffering capacity. . GT1-7 cells were transfected with siRNA against NR1 for 72 hours, which resulted in reduced NR1 protein expression (A), that is quantified in optical density units (B; *p<0.001). C. Mitochondria isolated from cells transfected with siRNA or scramble RNA that were exposed to calcium, had baseline (control) [Ca 2+ ] m levels. As previously demonstrated, mitochondria prepared from control cells and exposed to both calcium and NMDA showed a two-fold increase in [Ca 2+ ] m . In contrast, cells in which NR1 was knocked down failed 
